Avalo Therapeutics(AVTX) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates WAYNE, PA, May 12, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025. "We have made considerable progress in our Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with site activations, screenings and enrollment progress all in line with our ori ...